Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Zanamivir (Dectova®) is recommended as an option for use within NHS Wales for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥ 6 months) when: the patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient. Zanamivir (Dectova®) should be used in accordance with official guidance. |
|||
|
|||
Medicine details |
|||
| Medicine name | zanamivir (Dectova®) | ||
| Formulation | 10 mg/ml solution for infusion | ||
| Reference number | 4130 | ||
| Indication | Treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥ 6 months) when: the patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient. Zanamivir (Dectova®) should be used in accordance with official guidance |
||
| Company | GlaxoSmithKline UK | ||
| BNF chapter | Infections | ||
| Assessment type | Limited | ||
| Status | Recommended | ||
| Advice number | 1219 | ||
| NMG meeting date | 04/09/2019 | ||
| AWMSG meeting date | 16/10/2019 | ||
| Date of issue | 24/10/2019 | ||
| Date of last review | December 2022 | ||